Novo Nordisks Wegovy cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular diseas
Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater…